IDH1 and central nervous system cancer: This combination incorporates immune and metabolic factors, not only accurately predicting the prognosis, but also distinguishing different glioma molecular subtypes, including IDH1 mutation, MGMT promoter methylation, and 1p/19q co-deletion.